Business Context and Reporting Period
Company: NovaBridge Biosciences (formerly I-Mab)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Nine months ended September 30, 2025
Filing Date: December 18, 2025
NovaBridge is a global biotechnology platform company focused on developing innovative treatments, primarily in oncology. In October 2025, the company changed its name from I-Mab and adopted a new business model to transition into a biotechnology platform company with specialized subsidiaries. The company divested its Greater China assets and business operations in April 2024, ceasing consolidation of those entities. As of September 30, 2025, the company has no approved commercial products and has not generated product revenue.
Key Financial Metrics
| Metric | Nine Months Ended Sep 30, 2025 | Nine Months Ended Sep 30, 2024 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Net Loss | $(15.5) million | $(11.4) million |
| Loss from Continuing Operations | $(15.5) million | $(38.9) million |
| Research & Development Expenses | $(7.2) million | $(15.7) million |
| Administrative Expenses | $(14.1) million | $(22.3) million |
| Interest Income | $5.8 million | $5.3 million |
| Cash and Cash Equivalents (Sep 30, 2025) | $228.1 million | N/A |
| Short-term Investments (Sep 30, 2025) | $0.2 million | N/A |
| Net Cash Used in Operating Activities | $(6.0) million | $(41.7) million |
| Net Cash Generated from Financing Activities | $60.7 million | $(0.3) million |
Note: All figures in millions unless otherwise noted. The 2024 Net Loss includes a $27.5 million gain from discontinued operations related to the divestiture of Greater China assets.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $16.7 million (43.8%) compared to the prior year. R&D expenses dropped 54.0% and Administrative expenses dropped 36.7%, primarily due to lower headcount, reduced employee benefits, and cost-sharing reimbursements from collaboration agreements.
- Discontinued Operations: The 2024 period included a significant one-time gain of $34.4 million from the sale of discontinued operations (Greater China assets), which is not present in the 2025 period. Consequently, the 2025 Net Loss from continuing operations is a more accurate reflection of ongoing operational performance.
- Cash Position: Cash and cash equivalents increased significantly from $68.3 million at year-end 2024 to $228.1 million at September 30, 2025. This increase was driven by a $61.2 million underwritten offering of ADSs in August 2025 and net proceeds from investing activities ($105.0 million).
- Other Income/Expense: Other income (expenses) improved from a net expense of $(5.0) million in 2024 to net income of $0.1 million in 2025. The 2024 figure was heavily impacted by the settlement of TJ Biopharma repurchase obligations and fair value changes of put right liabilities, which were extinguished in 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management believes current cash, cash equivalents, and short-term investments of $228.3 million are sufficient to meet working capital and capital expenditure requirements for at least the next 12 months.
- Strategic Shift: The company is transitioning to a platform model with specialized subsidiaries. It has paused internal development of uliledlimab pending data from TJ Biopharma's Phase 2 study in China.
- Future Funding: The company anticipates continuing losses and will require additional capital to complete drug development and commercialization. Future funding may come from equity/debt financings, collaborations, or licensing.
Recent Developments (Subsequent to Period End)
- Hong Kong IPO: Filed an application on October 31, 2025, for a dual primary listing on the Hong Kong Stock Exchange.
- Visara Acquisition: Established Visara, Inc. to develop VIS-101 (ophthalmology). NovaBridge invested $37 million and made upfront payments of $5 million to AffaMed and $7 million to AskGene (later reimbursed by Everest Medicines).
- Bridge Health Acquisition: Acquired 100% of Bridge Health Biotech Co., Ltd. for an upfront payment of $1.8 million plus non-contingent and milestone payments.
Risks and Contingencies
- Regulatory and Clinical Risk: Success depends on advancing drug candidates (givastomig, VIS-101, etc.) through clinical trials and obtaining regulatory approval.
- Financial Risk: The company has a history of losses and negative cash flows. Failure to raise additional capital could force delays or termination of development programs.
- Legal Proceedings: Arbitration regarding the divestiture of Greater China assets was settled in the second half of 2024. A trade secret litigation against Inhibrx, Inc. resulted in a jury finding in favor of the defendants in November 2024 regarding a portion of the claims.
Key Facts for Investor Verification
- Cash Runway: Verify the $228.3 million cash balance and the 12-month liquidity projection against current burn rates.
- Revenue Model: Confirm the timeline for potential revenue generation, as the company currently has $0 revenue and relies on out-licensing or future product sales.
- Pipeline Progress: Monitor the status of the global randomized Phase 2 study for givastomig and the Phase 2a study for VIS-101.
- Contingent Consideration: Review the terms of the $80 million contingent consideration from the divestiture of Greater China assets to TJ Biopharma, which depends on future regulatory and sales milestones.
- Share Dilution: Assess the impact of the recent underwritten offering (33.3 million ADSs) and potential future financing needs on shareholder dilution.